(Q40550294)

English

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

scientific article published on October 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles (English)

1 reference

Europe PubMed Central

21 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

mixed hyperlipidemia

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1016/S0021-9150(03)00296-X

https://api.crossref.org/works/10.1016/S0021-9150(03)00296-X

31 March 2024

1

object named as

Tzung-Dau Wang

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612213

31 March 2024

author name string

Wen-Jone Chen

2

1 reference

Europe PubMed Central

21 September 2017

Jong-Wei Lin

3

1 reference

Europe PubMed Central

21 September 2017

Ching-Chih Cheng

4

1 reference

Europe PubMed Central

21 September 2017

Ming-Fong Chen

5

1 reference

Europe PubMed Central

21 September 2017

Yuan-Teh Lee

6

1 reference

Europe PubMed Central

21 September 2017

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14612213

31 March 2024

publication date

1 October 2003

1 reference

Europe PubMed Central

21 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S002191500300296X?httpAccept=text/xml

1 reference

10.1016/S0021-9150(03)00296-X

https://api.crossref.org/works/10.1016/S0021-9150(03)00296-X

31 March 2024

https://api.elsevier.com/content/article/PII:S002191500300296X?httpAccept=text/plain

1 reference

10.1016/S0021-9150(03)00296-X

https://api.crossref.org/works/10.1016/S0021-9150(03)00296-X

31 March 2024

Atherosclerosis

1 reference

Europe PubMed Central

21 September 2017

170

1 reference

Europe PubMed Central

21 September 2017

2

1 reference

Europe PubMed Central

21 September 2017

315-323

1 reference

Europe PubMed Central

21 September 2017

Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. For the Simvastatin Combined Hyperlipidemia Registry Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Atherosclerosis. the road ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Inflammation markers and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Requirement for CD154 in the progression of atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Soluble CD40 Ligand in Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Soluble CD40L and cardiovascular risk in women

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Low high-density lipoprotein cholesterol and response to simvastatin therapy in Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900296-X

7 January 2021

Identifiers

10.1016/S0021-9150(03)00296-X

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40550294&oldid=2115619066"